Save The Date: November 1-2, 2017
10 on the Park, New York City

2015 Speakers

2015 Speakers and Participants

  • Karen Akinsanya, Head, Early Stage Assessment, Merck
  • Vincent Andrews, Associate General Counsel, Eisai, Inc.
  • Sharon Benzeno, PhD, MBA, Senior Director of New Product Development, Adaptive Biotechnologies Corp.
  • Laurence Blumberg MD, President and Chief Executive Officer, Syntimmune Inc
  • Jeffrey M. Bockman, PhD, Vice President, Defined Health
  • Jarrod Borkat , Head, External Collaborations and Biotech Hubs, MedImmune
  • Ellen B. Corenswet, Partner, Covington & Burling LLP
  • Janet L. Dally, Founder, Maidstone Life Sciences
  • Peter DeLuca, Partner, Carter, DeLuca, Farrell & Schmidt, LLP
  • Pamela R. Demain, Executive Director, Transactions, Business
  • Development & Licensing, Merck ­­­
  • Kathleen A. Denis, PhD, Associate Vice President, Technology Transfer, The Rockefeller University
  • Kate de Santis, Vice President of Investor Relations, Iroko Pharmaceuticals, LLC
  • Ashish Dugar, PhD, MBA, Vice President, Commercial Development, Intra-Cellular Therapies, Inc.
  • Thomas Gallagher, Senior Vice President, Intellectual Property, Kadmon Corporation
  • Inna Grodzovski, PhD, Senior Analyst, FreeMind Group
  • Joseph V. Gulfo, MD, MBA, Rothman Institute of Innovation & Entrepreneurship, Fairleigh Dickinson University
  • Michael Gutch, PhD, Executive Director – Corporate Development, AstraZeneca
  • Kimberly Ha, Senior Director, FTI Consulting
  • Andrew Hass, Senior Advisor, Oncology Search & Evaluation, Eli Lilly and Company
  • Claudia Hirawat, President, PTC Therapeutics, Inc. (retired)
  • Nouhad Husseini, Senior Director, Business Development, Regeneron Pharmaceuticals
  • Ginger S. Johnson, PhD, Vice President, Defined Health
  • Anna Kazanchyan, MD, Senior Vice President, Business Development, Ovid Therapeutics Inc.
  • Kristen C. Kosofsky, Senior Managing Director for Life Sciences, Hercules Technology Growth Capital
  • Ann Kraft, Executive Director, Licensing & Business Development, Purdue Pharma LP
  • Steven Kreit, Partner, EisnerAmper
  • Ramesh Kumar, PhD, President & Chief Executive Officer, Onconova Therapeutics
  • Sanford J. Madigan, PhD, SVP, COI Pharmaceuticals, Inc.
  • Nagesh Mahanthappa, Ph.D., MBA, CEO & President, Scholar Rock
  • Kurt W. Marek, PhD, Deputy Director, Office of Translational Alliances and Coordination, Division of Extramural Research Activities, National Heart, Lung and Blood Institute, National Institutes of Health
  • Jules T. Mitchel, MBA, PhD, President, Target Health, Inc.
  • Bernard Munos, MS, MBA, Senior Fellow, FasterCures
  • Marian T. Nakada, PhD, Vice President Venture Investments, Johnson & Johnson Development Corp.
  • Bill Newell, CEO, Sutro Biopharma, Inc.
  • Tim Opler, Partner, Torreya Partners
  • Brian P. O’Shaughnessy, Shareholder, RatnerPrestia, and Public Policy & Regional Vice President, Licensing Executives Society (LES)
  • Art Pappas, MBA, Managing Partner, Pappas Ventures
  • A. Antony Pfeffer, Partner, Kenyon & Kenyon
  • Ronit Phail, Senior Director, Search & Evaluation, Corporate Business Development, Eli Lilly and Company
  • William S. Podd, President and Executive Director, Landmark Angels, Inc.
  • Dennis J. Purcell, Managing Partner, Aisling Capital LLC
  • Carlo Rizzuto, PhD, CEO, Highline Therapeutics, Inc., Venture Partner, Versant Ventures
  • Barbara S. Schilberg, Managing Director and Chief Executive Officer, BioAdvance Ventures
  • Amy Schulman, Venture Partner, Polaris Partners
  • Reginald Seeto, MD, Vice President, Head of Partnering & Strategy, AstraZeneca/Medimmune
  • Lauren Shearman, PhD, Executive Director, CardioMetabolic Search and Evaluation, Merck
  • Todd T. Sherer, PhD, Chief Executive Officer, The Michael J. Fox Foundation
  • Eric Siemers, MD, Medical Director, Alzheimer’s Disease Team, Eli Lilly and Company
  • Mark Simon, Partner, Torreya Partners
  • Deborah A. Somerville, Partner, Kenyon & Kenyon LLP
  • Jeremy Springhorn, PhD, Partner, Flagship Ventures
  • Robert B. Stein, MD, PhD, Chief Scientific Officer, Agenus Inc.
  • Lesley Stolz, PhD, Transactions Team, California Innovation Center, Johnson & Johnson Innovation
  • Amir P. Tamiz, PhD, Program Director, Office of Translational Research, National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Health
  • Daniel Teper, PharmD, Chief Executive Officer, Immune Pharmaceuticals
  • Marc Tessier-Lavigne, PhD, President, The Rockefeller University
  • Gregory Q. Tiberend, President & Chief Executive Officer, Tiberend Strategic Advisors, Inc.
  • Peter Young, Executive-in-Residence, A.M. Pappas & Associates
  • Eric Victory, Vice President & Head for Cardiovascular & Metabolic Disease, Partnering & Strategy, MedImmune
  • Chris Vlahos, PhD, Director Global External R&D, Eli Lilly and Company
  • Felicia Vonella, Director, Investor Relations & Corporate Communications, Acorda Therapeutics
  • Stacie Weninger, PhD, Executive Director, F-Prime Capital Partners
  • Stephen D. Wolpe, PhD, Entrepreneur-in-Residence, BioHealth Innovation
  • Alex Zisson, Partner, Thomas, McNerney & Partners LLC